‘Pent-up demand’ for FDA-approved cannabis drug boosts UK maker
Strong patient interest in the only federally approved CBD product in the United States helped drugmaker GW Pharmaceuticals record…
News August 7
Latest In: GW Pharmaceuticals
GW Pharma’s cannabis drug OK’d by European Medicines Agency panel
GW Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) recommended approval of the British company’s…
News July 26
Epidiolex, Sativex maker GW Pharma reports Q1 revenue, loss improvement
United Kingdom-based GW Pharmaceuticals showed revenue of $39.2 million for the quarter ended March 31, 2019, compared with…
News May 6
GW Pharma denies supply issues with marijuana-based drug Epidiolex after stock falls
GW Pharmaceuticals, the British maker of epileptic seizure-control medication Epidiolex, said it was not aware of any supply…
News February 21
Weekly Deal Watch: Cannabis investor demand shifts from Canada to US
Canadian investors are turning their attention to the U.S., as multistate operators continue to build their infrastructure.
News October 10
CBD drugmaker GW Pharmaceuticals poised to raise $300 million
GW Pharmaceuticals is setting out to sell $300 million worth of U.S. depository shares.
News October 2
DEA moves some CBD medicines off Schedule 1, a limited expansion of cannabis access
The U.S. Drug Enforcement Administration has taken some cannabidiol off the most restrictive class of controlled substances, a move that…
News September 27
United Kingdom legalizes medical cannabis prescriptions
Medical marijuana will be available by prescription in the United Kingdom by autumn after it was formally approved…
News July 26
British tobacco giant Imperial Brands invests in medical marijuana
British tobacco giant Imperial Brands is among a group of investors taking a stake in a UK-based medial…
News June 29Featured
1
Latest Sponsored
